Close Menu

NEW YORK (360Dx) – BioMérieux said today that the US Food and Drug Administration has provided clearance for the expanded use of the firm's Vidas Brahms PCT Assay, an automated test that measures levels of procalcitonin, to aid clinical decisions about the optimal use of antibiotics in patients with lower respiratory tract infections or sepsis. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.